# Iterum Therapeutics

**Canonical:** https://apis.io/providers/iterum-therapeutics/  
**Website:** https://www.iterumtx.com  
**APIs profiled:** 0

Iterum Therapeutics plc is a clinical-stage pharmaceutical company headquartered in Dublin, Ireland, focused on developing novel anti-infective medications to treat multi-drug resistant (MDR) bacterial infections. Its lead product, ORLYNVAH (sulopenem), is described as the first oral and IV penem antibiotic targeting gram-negative resistant infections. The company was surfaced as a portfolio company of canaan-partners and added to the API Evangelist network. Iterum Therapeutics is a pharmaceutical/biotech company and does not operate a public developer API; as of March 2026 the company entered liquidation following a High Court order in Ireland.

## Kin Score — 8.9 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 8.9).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 4.8 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 10.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Pharmaceuticals, Biotechnology, Anti-Infectives, Antibiotics, Healthcare, Clinical Stage, Drug Development

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/iterum-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.